Xeloda (capecitabine) is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered systemic prodrug of 5'-deoxy-5-fluorouridine which is converted to 5'-fluorouracil. It is often used in combination with other antineoplastic drugs.

Pre-authorization Criteria:

Metastatic breast cancer:
Monotherapy: Treatment of metastatic breast cancer resistant to both paclitaxel (Taxol) and an anthracycline-containing regimen (e.g. Adriamycin), or resistant to paclitaxel in patients for whom further anthracycline therapy is not indicated
Combination therapy: Treatment of metastatic breast cancer (in combination with docetaxel [Taxotere]) after failure of a prior anthracycline-containing regimen

Metastatic colorectal cancer: First-line treatment of metastatic colorectal cancer when treatment with a fluoropyrimidine alone is preferred; adjuvant therapy of Dukes' C colon cancer after complete resection of the primary tumor when fluoropyrimidine therapy alone is preferred

Dosing:

Breast cancer: oral 1,250 mg/m² twice daily for 2 weeks, every 21 days (as either monotherapy or in combination with docetaxel)

Colorectal cancer: oral 1,250 mg/m² twice daily for 2 weeks, every 21 days

Note: Use in other cancers is off-label. Please see the VCHCP Coverage of Prescription Medication for Off-Label Use policy.
How Supplied: tablets 150 mg, 500 mg

**Adverse Reactions/Precautions:** Black Box Warning (potentiates the effect of warfarin); bone marrow suppression; cardiotoxicity; hepatotoxicity diarrhea; hand and foot syndrome (palmar-plantar erythrodysesthesia);

**Drug Interactions:** capecitabine inhibits CYP2C9; use caution with other drugs metabolized by CYP2C9 (e.g. cannabis, carvedilol, diclofenac, fosphenytoin, phenytoin, some Q-T prolonging drugs); some drugs may decrease effectiveness of capecitabine (e.g. PPIs)

**REFERENCES:**


Xeloda (capecitabine) [prescribing information]. South San Francisco, CA: Genentech USA, Inc; March 2015.

Xeloda (capecitabine) [product monograph]. Mississauga, Ontario: Hoffmann-La Roche Limited; March 2016.

UpToDate 2017: Capecitabine: Drug information
Revision History:

Date Developed: 11/30/16 by R. Sterling, MD
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/22/19</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>2/18/20</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>